Literature DB >> 25998395

Dynamic range of Nef-mediated evasion of HLA class II-restricted immune responses in early HIV-1 infection.

Macdonald Mahiti1, Zabrina L Brumme2, Heiko Jessen3, Mark A Brockman2, Takamasa Ueno4.   

Abstract

HLA class II-restricted CD4(+) T lymphocytes play an important role in controlling HIV-1 replication, especially in the acute/early infection stage. But, HIV-1 Nef counteracts this immune response by down-regulating HLA-DR and up-regulating the invariant chain associated with immature HLA-II (Ii). Although functional heterogeneity of various Nef activities, including down-regulation of HLA class I (HLA-I), is well documented, our understanding of Nef-mediated evasion of HLA-II-restricted immune responses during acute/early infection remains limited. Here, we examined the ability of Nef clones from 47 subjects with acute/early progressive infection and 46 subjects with chronic progressive infection to up-regulate Ii and down-regulate HLA-DR and HLA-I from the surface of HIV-infected cells. HLA-I down-regulation function was preserved among acute/early Nef clones, whereas both HLA-DR down-regulation and Ii up-regulation functions displayed relatively broad dynamic ranges. Nef's ability to down-regulate HLA-DR and up-regulate Ii correlated positively at this stage, suggesting they are functionally linked in vivo. Acute/early Nef clones also exhibited higher HLA-DR down-regulation and lower Ii up-regulation functions compared to chronic Nef clones. Taken together, our results support enhanced Nef-mediated HLA class II immune evasion activities in acute/early compared to chronic infection, highlighting the potential importance of these functions following transmission.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HIV-1; HLA class I; HLA class II; Immune evasion; Nef

Mesh:

Substances:

Year:  2015        PMID: 25998395     DOI: 10.1016/j.bbrc.2015.05.038

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  Differential Ability of Primary HIV-1 Nef Isolates To Downregulate HIV-1 Entry Receptors.

Authors:  Mako Toyoda; Yoko Ogata; Macdonald Mahiti; Yosuke Maeda; Xiaomei T Kuang; Toshiyuki Miura; Heiko Jessen; Bruce D Walker; Mark A Brockman; Zabrina L Brumme; Takamasa Ueno
Journal:  J Virol       Date:  2015-07-15       Impact factor: 5.103

2.  HLA Class I Downregulation by HIV-1 Variants from Subtype C Transmission Pairs.

Authors:  Zachary Ende; Martin J Deymier; Daniel T Claiborne; Jessica L Prince; Daniela C Mónaco; William Kilembe; Susan A Allen; Eric Hunter
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

3.  Resistance of Major Histocompatibility Complex Class B (MHC-B) to Nef-Mediated Downregulation Relative to that of MHC-A Is Conserved among Primate Lentiviruses and Influences Antiviral T Cell Responses in HIV-1-Infected Individuals.

Authors:  Francis Mwimanzi; Mako Toyoda; Macdonald Mahiti; Jaclyn K Mann; Jeffrey N Martin; David Bangsberg; Mark A Brockman; Philip Goulder; Frank Kirchhoff; Zabrina L Brumme; Thumbi Ndung'u; Takamasa Ueno
Journal:  J Virol       Date:  2017-12-14       Impact factor: 5.103

4.  Relative Resistance of HLA-B to Downregulation by Naturally Occurring HIV-1 Nef Sequences.

Authors:  Macdonald Mahiti; Mako Toyoda; Xiaofei Jia; Xiaomei T Kuang; Francis Mwimanzi; Philip Mwimanzi; Bruce D Walker; Yong Xiong; Zabrina L Brumme; Mark A Brockman; Takamasa Ueno
Journal:  MBio       Date:  2016-01-19       Impact factor: 7.867

5.  Modelling and in vitro testing of the HIV-1 Nef fitness landscape.

Authors:  John P Barton; Erasha Rajkoomar; Jaclyn K Mann; Dariusz K Murakowski; Mako Toyoda; Macdonald Mahiti; Phillip Mwimanzi; Takamasa Ueno; Arup K Chakraborty; Thumbi Ndung'u
Journal:  Virus Evol       Date:  2019-08-05

6.  Impaired ability of Nef to counteract SERINC5 is associated with reduced plasma viremia in HIV-infected individuals.

Authors:  Mako Toyoda; Doreen Kamori; Toong Seng Tan; Kageaki Goebuchi; Jun Ohashi; Jonathan Carlson; Ai Kawana-Tachikawa; Hiroyuki Gatanaga; Shinichi Oka; Massimo Pizzato; Takamasa Ueno
Journal:  Sci Rep       Date:  2020-11-10       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.